The R21/Matrix-M™ malaria vaccine, jointly developed through a collaboration between the Jenner Institute at Oxford University and the Serum Institute of India (SII), utilizing Novavax’s saponin-based adjuvant technology, is the second malaria vaccine authorized for use in children in malaria-endemic regions.

According to a statement from the company, a total of 163,800 doses of the malaria vaccine are specifically allocated for the Central African Republic (CAR) region, with 43,200 doses already dispatched from the Serum Institute of India facility. Click here to read more.